Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Volume Plasma Exchange and GCSF in ACLF
NCT03162419Withdrawn
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2017
- Primary completion
- Apr 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of granulocyte colony-stimulating factor and High-Volume Plasma Exchange + GCSF in acute-on-chronic liver failure (ACLF) (3 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Transplant-free survival at 28 days. Planned start May 2017; status: withdrawn.
02
Drugs
granulocyte colony-stimulating factorHigh-Volume Plasma Exchange + GCSF
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03162419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162419.